• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Illuccix Receives European Approval

    GLOBENEWSWIRE

    Illuccix® Receives European Approval

    GLOBENEWSWIRE

    Scintimun® Commercialization Partnership with Curium Pharma

    PR NEWSWIRE

    Telix To Acquire Next-Gen Therapeutic Assets & Technology Platform

    PR NEWSWIRE

    Telix To Acquire Therapeutic Asset & Biologics Technology Platform

    GLOBENEWSWIRE

    Businessperson of the year 2024- Dr Christian (Telix Pharma)

    BIOSPACE

    TLX599-CDx PSMA Imaging of Prostate Cancer Published

    GLOBENEWSWIRE

    Telix Files TLX250-CDx BLA for Kidney Cancer Imaging

    GLOBENEWSWIRE

    Telix Completes Cyclotron Installation at Brussels South Facility

    PR NEWSWIRE

    Telix Manufacturing, Brussel South Complete Cyclotron Installation

    GLOBENEWSWIRE

    Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

    PR NEWSWIRE

    Telix & Eckert & Ziegler to Partner on Actinium-225 Technology

    GLOBENEWSWIRE

    Telix ADSs Commence Trading on Nasdaq

    GLOBENEWSWIRE

    Telix Welcomes CMS Decision on Diagnostic Radiopharmaceuticals

    GLOBENEWSWIRE

    Telix Partners with Subtle Medical for AI-Enabled Imaging

    GLOBENEWSWIRE

    FDA Accepts TLX101-CDx New Drug Application for Brain Cancer

    GLOBENEWSWIRE

    Telix Spins Off Rhine To Expand Access To Radiopharmaceuticals

    PR NEWSWIRE

    After buyouts, Telix unveils new radiopharma spinoff Rhine

    FIERCE PHARMA

    Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M

    GLOBENEWSWIRE

    Telix Files Form 20-F Registration Statement for Nasdaq ADS

    GLOBENEWSWIRE

    Telix Featured In 13 Abstracts At EANM Annual Congress

    PR NEWSWIRE

    Health Canada Approves Label Expansion For Telix`s Illuccix

    GLOBENEWSWIRE

    First Patient Dosed In CA-NINE Trial For Kidney Cancer Detection

    GLOBENEWSWIRE

    Telix Pharma Buys RLS For $230M To Build Radiometal Network

    BIOSPECTRUM ASIA

    Telix Acquires RLS

    CONTRACT PHARMA

    Telix To Acquire RLS To Expand North American Manufacture Platform

    PR NEWSWIRE

    Cullinan Approved to Start Phase 1 Trial of CLN-978

    GLOBENEWSWIRE

    Telix`s ZIRCON Trial For Kidney Cancer Published In Lancet

    GLOBENEWSWIRE

    Telix`s ZIRCON Trial Published In The Lancet Oncology

    PR NEWSWIRE

    TLX101 Glioblastoma Therapy Study Published in Neuro-Oncology Advances

    GLOBENEWSWIRE

    Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

    PR NEWSWIRE

    Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent

    GLOBENEWSWIRE

    Telix Announces Reorganisation to Deliver on Strategic Priorities

    PR NEWSWIRE

    Telix Reports Strong H1 2024 Revenue And Profit Growth

    GLOBENEWSWIRE

    Telix Opens U.S. Expanded Access For TLX101-CDx Glioma Imaging Agent

    GLOBENEWSWIRE

    FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent

    GLOBENEWSWIRE

    Q2 2024 Revenue and Business Highlights, Guidance Upgrade

    GLOBENEWSWIRE

    Telix Welcomes CMS Proposal For Diagnostic Radiopharmaceutical Payment

    GLOBENEWSWIRE

    Telix Elects to Withdraw from Proposed U.S. Listing

    PRESS RELEASE

    Telix Announces Launch of Proposed Initial Public Offering in the United States

    GLOBENEWSWIRE

    Telix Completes Zircaix BLA Submission For Kidney Cancer Imaging

    GLOBENEWSWIRE

    Telix Positive rPFS Data For TLX591 Prostate Cancer Candidate

    PR NEWSWIRE

    Telix Announces Positive rPFS Data For TLX591 In Prostate Cancer Trial

    GLOBENEWSWIRE

    Telix Submits NDA for New Prostate Cancer Imaging Agent

    GLOBENEWSWIRE

    Telix Completes Prostate Cancer TLX592 Targeted Alpha Therapy POC

    PR NEWSWIRE

    Telix Completes Prostate Cancer TLX592 Targeted Alpha Therapy POC Study

    GLOBENEWSWIRE

    Australian radiopharmaceutical biotech Telix files for a $100 million US IPO

    RENAISSANCECAPITAL

    Q1 2024 Revenue and Business Update

    GLOBENEWSWIRE

    TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

    GLOBENEWSWIRE

    Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.

    BUSINESSWIRE

    World First Use of Lightpoint`s SENSEI® Drop-In Gamma Probe in Surgery

    GLOBENEWSWIRE

    First Patient Dosed in Italian Named Patient Program for TLX250-CDx

    PR NEWSWIRE

    QDOSE® Platform Partnership for Personalized Dosimetry

    GLOBENEWSWIRE

    Appointment of Dr Darren Patti to Group Chief Operating Officer

    GLOBENEWSWIRE

    Telix takes on isotope manufacturer ARTMS for up to $82M

    FIERCE PHARMA

    Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

    GLOBENEWSWIRE

    Telix boosts in-house radiopharma manufacturing

    ENDPTS

    Telix moves to acquire CDMO IsoTherapeutics in $13.6M deal

    FIERCE PHARMA

    Telix Pharma expands US infrastructure with acquisition of IsoTherapeutics

    BIOSPECTRUM ASIA

    Telix 2023 Full Year Results: Inaugural Profit Achieved

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.